We thank Jiale Chen and Xiaoyuan Xu for suggesting presentation of absolute risks of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 and above, and 3 and above, symptomatic adverse events and corresponding risk differences between study groups to illustrate the added value of PRO data for adverse event identification. For each adverse event, we calculated the proportion of patients with the highest grade 2 and 3 or above per group, using the higher of the two available ratings (worst toxicity reported).
The Lancet Oncology published a clinical update in Oncology on 01 Apr 2026.
The item focuses on From reliability to implementable toxicity policy in PRO-informed CTCAE – Authors' reply.
Review the original article for the full source wording and details.